Dr. David E. Einspahr
Claim this profileCotton O'Neil Cancer Center / Stormont Vail Health
Area of expertise
Lung Cancer
David E. Einspahr has run 4 trials for Lung Cancer. Some of their research focus areas include:
Non-Small Cell Lung Cancer
David E. Einspahr has run 3 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
Cotton O'Neil Cancer Center / Stormont Vail Health
Cotton O'Neil Cancer Center (Stormont-Vail Cancer Center)
Clinical Trials David E. Einspahr is currently running
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
Hormone Therapy + Radiation
for Prostate Cancer
This phase III trial uses the Decipher risk score to guide therapy selection. Decipher score is based on the activity of 22 genes in prostate tumor and may predict how likely it is for recurrent prostate cancer to spread (metastasize) to other parts of the body. Decipher score in this study is used for patient selection and the two variations of treatment to be studied: intensification for higher Decipher score or de-intensification for low Decipher score. Patients with higher Decipher risk score will be assigned to the part of the study that compares the use of 6 months of the usual treatment (hormone therapy and radiation treatment) to the use of darolutamide plus the usual treatment (intensification). The purpose of this section of the study is to determine whether the additional drug can reduce the chance of cancer coming back and spreading in patients with higher Decipher score. The addition of darolutamide to the usual treatment may better control the cancer and prevent it from spreading. Alternatively, patients with low Decipher risk score will be assigned to the part of the study that compares the use of radiation treatment alone (de-intensification) to the usual approach (6 months of hormone therapy plus radiation). The purpose of this part of the study is to determine if radiation treatment alone is as effective compared to the usual treatment without affecting the chance of tumor coming back in patients with low Decipher score prostate cancer. Radiation therapy uses high energy to kill tumor cells and reduce the tumor size. Hormone therapy drugs such as darolutamide suppress or block the production or action of male hormones that play role in prostate cancer development. Effect of radiation treatment alone in patients with low Decipher score prostate cancer could be the same as the usual approach in stabilizing prostate cancer and preventing it from spreading, while avoiding the side effects associated with hormonal therapy.
Recruiting
2 awards
Phase 3
1 criteria
More about David E. Einspahr
Clinical Trial Related
6 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments David E. Einspahr has experience with
- Carboplatin
- Paclitaxel
- Pembrolizumab
- Pemetrexed Disodium
- Gemcitabine Hydrochloride
- Gemcitabine
Breakdown of trials David E. Einspahr has run
Lung Cancer
Non-Small Cell Lung Cancer
Anaplastic Large Cell Lymphoma
ALK Gene Rearrangement
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David E. Einspahr specialize in?
David E. Einspahr focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage II patients, or patients who are Stage I.
Is David E. Einspahr currently recruiting for clinical trials?
Yes, David E. Einspahr is currently recruiting for 2 clinical trials in Topeka Kansas. If you're interested in participating, you should apply.
Are there any treatments that David E. Einspahr has studied deeply?
Yes, David E. Einspahr has studied treatments such as Carboplatin, Paclitaxel, Pembrolizumab.
What is the best way to schedule an appointment with David E. Einspahr?
Apply for one of the trials that David E. Einspahr is conducting.
What is the office address of David E. Einspahr?
The office of David E. Einspahr is located at: Cotton O'Neil Cancer Center / Stormont Vail Health, Topeka, Kansas 66606 United States. This is the address for their practice at the Cotton O'Neil Cancer Center / Stormont Vail Health.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.